Kalaris Therapeutics Statistics
Total Valuation
KLRS has a market cap or net worth of $110.06 million. The enterprise value is $34.61 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KLRS has 18.70 million shares outstanding. The number of shares has increased by 514.28% in one year.
| Current Share Class | 18.70M |
| Shares Outstanding | 18.70M |
| Shares Change (YoY) | +514.28% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 9.02% |
| Owned by Institutions (%) | 9.51% |
| Float | 4.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.63 |
| P/TBV Ratio | 2.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.89, with a Debt / Equity ratio of 0.04.
| Current Ratio | 12.89 |
| Quick Ratio | 12.70 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.09 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -63.50% |
| Return on Invested Capital (ROIC) | -572.13% |
| Return on Capital Employed (ROCE) | -56.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.96M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 5.55 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 52.85 |
| Average Volume (20 Days) | 161,590 |
Short Selling Information
The latest short interest is 428,091, so 2.29% of the outstanding shares have been sold short.
| Short Interest | 428,091 |
| Short Previous Month | 403,085 |
| Short % of Shares Out | 2.29% |
| Short % of Float | 9.25% |
| Short Ratio (days to cover) | 1.12 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.48M |
| Pretax Income | -55.47M |
| Net Income | -55.47M |
| EBITDA | n/a |
| EBIT | -42.48M |
| Earnings Per Share (EPS) | -$3.46 |
Full Income StatementBalance Sheet
The company has $77.00 million in cash and $1.55 million in debt, giving a net cash position of $75.45 million or $4.03 per share.
| Cash & Cash Equivalents | 77.00M |
| Total Debt | 1.55M |
| Net Cash | 75.45M |
| Net Cash Per Share | $4.03 |
| Equity (Book Value) | 41.87M |
| Book Value Per Share | 2.24 |
| Working Capital | 72.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$39.16 million and capital expenditures -$183,000, giving a free cash flow of -$39.35 million.
| Operating Cash Flow | -39.16M |
| Capital Expenditures | -183,000 |
| Free Cash Flow | -39.35M |
| FCF Per Share | -$2.10 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |